| Meta-analysis | Sensitivity analysesa | ||||
---|---|---|---|---|---|---|
Outcome measures | RR | 95Â % CI | P | RR | 95Â % CI | P |
TCZCOMBI vs. TCZMONO | ||||||
 DAS28 < 2.6 | 1.21 | 1.09, 1.36 | <0.001 | 1.20 | 1.07, 1.34 | 0.002 |
 ACR20 | 1.05 | 0.99, 1.12 | 0.11 | 1.05 | 0.98, 1.11 | 0.17 |
 ACR50 | 1.14 | 1.03, 1.26 | 0.008 | 1.13 | 1.02, 1.25 | 0.02 |
 ACR70 | 1.19 | 0.94, 1.51 | 0.14 | 1.12 | 0.95, 1.33 | 0.19 |
 AEs | 1.08 | 0.97, 1.21 | 0.17 | 1.09 | 0.86, 1.38 | 0.48 |
 SAEs | 1.40 | 1.03, 1.92 | 0.03 | 1.34 | 0.79, 2.27 | 0.27 |
TCZCOMBI vs. csDMARD | ||||||
 DAS28 < 2.6 | 8.77 | 4.10, 18.75 | <0.001 | 10.39 | 4.38, 24.65 | <0.001 |
 ACR20 | 2.10 | 1.48, 2.99 | <0.001 | 2.15 | 1.45, 3.19 | <0.001 |
 ACR50 | 3.00 | 1.80, 4.99 | <0.001 | 3.24 | 1.82, 5.78 | <0.001 |
 ACR70 | 5.32 | 2.31, 12.25 | <0.001 | 6.23 | 2.29, 16.93 | <0.001 |
 AEs | 1.12 | 1.06, 1.18 | <0.001 | 1.14 | 1.07, 1.20 | <0.001 |
 SAEs | 1.21 | 0.91, 1.60 | 0.19 | 1.13 | 0.80, 1.60 | 0.48 |
TCZMONO vs. csDMARD | ||||||
 DAS28 < 2.6 | 3.95 | 2.23, 7.00 | <0.001 | 4.50 | 2.34, 8.64 | <0.001 |
 ACR20 | 1.68 | 1.21, 2.32 | 0.002 | 1.71 | 1.18, 2.48 | 0.005 |
 ACR50 | 1.87 | 1.19, 2.95 | 0.007 | 2.01 | 1.18, 3.42 | 0.01 |
 ACR70 | 2.11 | 1.18, 3.78 | 0.01 | 2.49 | 1.29, 4.81 | 0.007 |
 AEs | 1.08 | 1.01, 1.15 | 0.03 | 1.13 | 0.92, 1.39 | 0.24 |
 SAEs | 1.21 | 0.87, 1.69 | 0.26 | 1.37 | 0.64, 2.93 | 0.42 |